Valiant Laboratories (BOM:543998) EBIT : ₹-49 Mil (TTM As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Valiant Laboratories EBIT?

Valiant Laboratories's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2024 was ₹17 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2024 was ₹-49 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Valiant Laboratories's annualized ROC % for the quarter that ended in Dec. 2024 was 0.25%. Valiant Laboratories's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was 3.01%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Valiant Laboratories's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was -1.39%.

Valiant Laboratories EBIT Historical Data

The historical data trend for Valiant Laboratories's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Valiant Laboratories EBIT Chart

Valiant Laboratories Annual Data

Trend

Mar21

Mar22

Mar23

Mar24

EBIT

488.07

417.77

383.90

-6.92

Valiant Laboratories Quarterly Data
	Mar21	Mar22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
EBIT	Get a 7-Day Free Trial							-50.26	-25.47	-1.09	-39.02	16.80

Competitive Comparison of Valiant Laboratories's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Valiant Laboratories's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Valiant Laboratories's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Valiant Laboratories's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Valiant Laboratories's EV-to-EBIT falls into.

Save Embed

;

Save Embed

;

Valiant Laboratories EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-49 Mil.

Valiant Laboratories (BOM:543998) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Valiant Laboratories's annualized ROC % for the quarter that ended in Dec. 2024 is calculated as:

	ROC % (Q: Dec. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2024 )	+	Invested Capital (Q: Dec. 2024 ))	/ count )
=	4.084 * ( 1 - -44.9% )	/	( (2374.434	+	0)	/ 1 )
=	5.917716	/	2374.434
=	0.25 %

where

	Invested Capital		(Q: Sep. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	3609.575	-	45.371	-	( 1189.77	-	max(0, 218.47	-	1913.564	+	1189.77	))
=	2374.434

	Invested Capital		(Q: Dec. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0	-	0	-	( 0	-	max(0, 0	-	0	+	0	))
=	0

Note: The Operating Income data used here is four times the quarterly (Dec. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Valiant Laboratories's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Sep. 2024		Q: Dec. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	67.212	/	( ( (1624.922 + max(611.597, 0))	+	(0 + max(0, 0)) )	/	1 )
=	67.212	/	( ( 2236.519	+	0 )	/	1 )
=	67.212	/	2236.519
=	3.01 %

where Working Capital is:

	Working Capital		(Q: Sep. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(285.477	+	51.638	+	386.374)	-	(45.371	+	0	+	66.521)
=	611.597

	Working Capital		(Q: Dec. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0)	-	(0	+	0	+	0)
=	0

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Valiant Laboratories's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2024 )
	=	-48.775	/	3518.524
	=	-1.39 %

Valiant Laboratories EBIT Related Terms

Thank you for viewing the detailed overview of Valiant Laboratories's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Valiant Laboratories Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Valiant Laboratories Ltd (BOM:543998) » Definitions » EBIT

Traded in Other Exchanges

VALIANTLAB:India

Address

Mulund Goregaon Link Road, 104, Udyog Kshetra, Mulund, MH, IND, 400080

Website

https://www.valiantlabs.in

Valiant Laboratories Ltd is an Active Pharmaceutical Ingredient (API)/Bulk Drug manufacturing company with having focus on manufacturing Paracetamol. Paracetamol is one of the widely used analgesics globally and is recommended as the first-line therapy in pain conditions by the World Health Organization. Paracetamol has several applications such as usage in the treatment of headaches, muscle aches, arthritis, backaches, toothaches, colds, and fever. It manufactures Paracetamol in various grades such as IP/BP/EP/USP, as per the pharmacopeia requirements of its customers.

Valiant Laboratories Headlines

No Headlines